ClinicalTrials.gg
CompletedNCT02066207Updated Aug 8, 2017

CKD-337 Drug Interaction Study

A Phase 1 interventional study of Fenofibrate and Atorvastatin in Dyslipidemia (Fredrickson Type Ⅱa) and Dyslipidemia (Fredrickson Type Ⅱb), sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-08.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing fenofibrate in Dyslipidemias — none open to participants now, none under way, none of them phase 3. Fenofibrate · Dyslipidemias.

Enrollment
10th of 16
30 · median 35
Started
2014
with 1 other
Phase 1
2 of 16
none open now
Registered
10th of 16
by date
Lead sponsor
1 of 16
Chong Kun Dang Pharmaceutical

Among the 16 studies testing fenofibrate in Dyslipidemias, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 2 in phase 1, and was the 10th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 16 studies testing fenofibrate in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About fenofibrate

Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing fenofibrate in Dyslipidemias as a file.
02

Study summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction between atorvastatin and fenofibrate in healthy subjects.

03

Conditions studied

  • Dyslipidemia (Fredrickson Type Ⅱa)
  • Dyslipidemia (Fredrickson Type Ⅱb)

Browse trials for

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A healthy male volunteer between 19 and 55 years old.
  • between 18.5 and 27.
  • Able to participate in the entire trial
  • Signed the form prior to study participation.

Exclusion criteria

Exclusion Criteria:

  • digestive system, cardiovascular system, respiratory system, endocrine system, hepatic system, renal system
  • sit SBP \< 100mmHg or sit SBP ≥ 150mmHg or sit DBP \< 70mmHg or sit DBP ≥ 100mmHg
  • Have acute infection history within 14 days
  • Have a allergic disease of need to treat
  • Have reactions history for IP or any specific drugs.
  • , ALT or Total > UNL * 1.5
  • Estimated \< 60 ml/min
  • Genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
  • A heavy smoker (cigarette > 10 cigarettes per day)
  • A heavy alcohol consumer (alcohol > 140g/week)
  • A heavy grapefruit consumer (more than 1cup per a day)
  • Have a history of drug abuse or showed a positive for urine drug test.
  • Administrated IP within 60 days prior to screening
  • Rhabdomyolysis include of having a history or family history of genetic muscle diseases
  • Positive for antibody, , antibody test
  • Previously donate whole blood within 60 days or component blood within 30 days
  • Subject takes ethical drug or herbal medicine within 30 days
  • Clinically significant laboratory test result
  • An impossible one who participates in clinical trial by investigator's decision including other reason
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Fenofibrate

    Subjects received Fenofibrate

    Drug: Fenofibrate

  • Experimental
    Atorvastatin

    Subjects received Atorvastatin

    Drug: Atorvastatin

  • Experimental
    Fenofibrate and Atorvastatin

    Subjects received Fenofibrate and Atorvastatin

    Drug: Fenofibrate · Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. AUCt, Cmax,ss of fenofibric acid and atorvastatin

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 h

Secondary outcomes

  1. Tmax,ss, Cmin,ss, t1/2, CL/Fss, Vd/Fss, %swing, Cav, %fluctuation

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 h

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Apr 2014, 0 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 0 months is below that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2014
First posted
Feb 19, 2014
StartActual
Mar 18, 2014
Primary completionActual
Apr 7, 2014
CompletionActual
May 29, 2014
Last update
Aug 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02066207
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
Mar 18, 2014
Primary completion
Apr 7, 2014
Completion
May 29, 2014
Last update
Aug 8, 2017

Study contacts

Wooseong Huh, M.D., Ph.D.
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fenofibrate · Atorvastatin

Start the discussion